The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
The Combined Effects of Tryptophan Starvation and Tryptophan Catabolites Down-Regulate T Cell Receptor ζ-Chain and Induce a Regulatory Phenotype in Naive T Cells
Open accessAbstract
Tryptophan catabolism is a tolerogenic effector system in regulatory T cell function, yet the general mechanisms whereby tryptophan catabolism affects T cell responses remain unclear. We provide evidence that the short-term, combined effects of tryptophan deprivation and tryptophan catabolites result in GCN2 kinase-dependent down-regulation of the TCR ζ-chain in murine CD8+ T cells. TCR ζ down-regulation can be demonstrated in vivo and is associated with an impaired cytotoxic effector function in vitro. The longer-term effects of tryptophan catabolism include the emergence of a regulatory phenotype in naive CD4+CD25− T cells via TGF-β induction of the forkhead transcription factor Foxp3. Such converted cells appear to be CD25+, CD69−, CD45RBlow, CD62L+, CTLA-4+, BTLAlow and GITR+, and are capable of effective control of diabetogenic T cells when transferred in vivo. Thus, both tryptophan starvation and tryptophan catabolites contribute to establishing a regulatory environment affecting CD8+ as well as CD4+ T cell function, and not only is tryptophan catabolism an effector mechanism of tolerance, but it also results in GCN2-dependent generation of autoimmune-preventive regulatory T cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chen, W., Jin, W., Hardegen, N., Lei, K.-J., Li, L., Marinos, N., McGrady, G., & Wahl, S. M. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030152 · Cited by 4,699
Sakaguchi, S. (2005) · Nature Immunology · doi:10.1038/ni1178 · Cited by 2,669
Prevention of Allogeneic Fetal Rejection by Tryptophan Catabolism
Munn, D. H., Zhou, M., Attwood, J. T., Bondarev, I., Conway, S. J., Marshall, B., Brown, C., & Mellor, A. L. (1998) · Science · doi:10.1126/science.281.5380.1191 · Cited by 2,585
Ido expression by dendritic cells: tolerance and tryptophan catabolism
Mellor, A. L., & Munn, D. H. (2004) · Nature Reviews Immunology · doi:10.1038/nri1457 · Cited by 2,341
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305 · cited 4×
“Discussion The immunosuppressive pathway of tryptophan catabolism has been implicated, with either protective or disease-promoting roles, in a variety of physiopathologic conditions, ranging from pregnancy (3) to transplantation (4), from autoimmunity (5) and inflammation (6, 7, 46) to neoplasia (11, 12).”
BackgroundInfluentialRegulatory T Cell Lineage Specification by the Forkhead Transcription Factor Foxp3
Fontenot, J. D., Rasmussen, J. P., Williams, L. M., Dooley, J. L., Farr, A. G., & Rudensky, A. Y. (2005) · Immunity · doi:10.1016/j.immuni.2005.01.016 · Cited by 2,279
CD4+CD25+ suppressor T cells: more questions than answers
Shevach, E. M. (2002) · Nature Reviews Immunology · doi:10.1038/nri821 · Cited by 2,110
Inhibition of T Cell Proliferation by Macrophage Tryptophan Catabolism
Munn, D. H., Shafizadeh, E., Attwood, J. T., Bondarev, I., Pashine, A., & Mellor, A. L. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.9.1363 · Cited by 1,623
Modulation of tryptophan catabolism by regulatory T cells
Fallarino, F., Grohmann, U., Hwang, K. W., Orabona, C., Vacca, C., Bianchi, R., Belladonna, M. L., Fioretti, M. C., Alegre, M.-L., & Puccetti, P. (2003) · Nature Immunology · doi:10.1038/ni1003 · Cited by 1,374
Self-citationNatural versus adaptive regulatory T cells
Bluestone, J. A., & Abbas, A. K. (2003) · Nature Reviews Immunology · doi:10.1038/nri1032 · Cited by 1,323
Cited by
The emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Zelante, T., Iannitti, R. G., Cunha, C., De Luca, A., Giovannini, G., Pieraccini, G., Zecchi, R., D’Angelo, C., Massi-Benedetti, C., Fallarino, F., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.08.003 · Cited by 2,614
“, 2011) and promotes Treg cell development (Fallarino et al., 2006; Mezrich et al., 2010).”
Self-citationAn Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells
Mezrich, J. D., Fechner, J. H., Zhang, X., Johnson, B. P., Burlingham, W. J., & Bradfield, C. A. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903670 · Cited by 1,601
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
Platten, M., Nollen, E. A. A., Röhrig, U. F., Fallarino, F., & Opitz, C. A. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0016-5 · Cited by 1,586
Self-citationAltered macrophage differentiation and immune dysfunction in tumor development
Sica, A., & Bronte, V. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31422 · Cited by 1,238
Indoleamine 2,3-dioxygenase and tumor-induced tolerance
Munn, D. H., & Mellor, A. L. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31178 · Cited by 1,078
Indoleamine 2,3 dioxygenase and metabolic control of immune responses
Munn, D. H., & Mellor, A. L. (2013) · Trends in Immunology · doi:10.1016/j.it.2012.10.001 · Cited by 1,037
IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance
Munn, D. H., & Mellor, A. L. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.002 · Cited by 1,041
Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy
Bader, J. E., Voss, K., & Rathmell, J. C. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.05.034 · Cited by 1,030
Regulation of the immune response by the aryl hydrocarbon receptor
Gutiérrez-Vázquez, C., & Quintana, F. J. (2018) · Immunity · doi:10.1016/j.immuni.2017.12.012 · Cited by 985
Metabolism of immune cells in cancer
Leone, R. D., & Powell, J. D. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0273-y · Cited by 877
Sharma, M. D., Baban, B., Chandler, P., Hou, D.-Y., Singh, N., Yagita, H., Azuma, M., Blazar, B. R., Mellor, A. L., & Munn, D. H. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31911 · Cited by 792
Molecular Mechanisms of Treg-Mediated T Cell Suppression
Schmidt, A., Oberle, N., & Krammer, P. H. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00051 · Cited by 761
Natural regulatory T cells: mechanisms of suppression
Miyara, M., & Sakaguchi, S. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.01.003 · Cited by 711
Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells
Pallotta, M. T., Orabona, C., Volpi, C., Vacca, C., Belladonna, M. L., Bianchi, R., Servillo, G., Brunacci, C., Calvitti, M., Bicciato, S., et al. (2011) · Nature Immunology · doi:10.1038/ni.2077 · Cited by 703
Self-citationTryptophan Catabolism in Cancer: Beyond IDO and Tryptophan Depletion
Platten, M., Wick, W., & Van den Eynde, B. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0569 · Cited by 703
François, M., Romieu-Mourez, R., Li, M., & Galipeau, J. (2012) · Molecular Therapy · doi:10.1038/mt.2011.189 · Cited by 694
Nguyen, N. T., Kimura, A., Nakahama, T., Chinen, I., Masuda, K., Nohara, K., Fujii-Kuriyama, Y., & Kishimoto, T. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014465107 · Cited by 685
Aryl hydrocarbon receptor control of a disease tolerance defence pathway
Bessede, A., Gargaro, M., Pallotta, M. T., Matino, D., Servillo, G., Brunacci, C., Bicciato, S., Mazza, E. M. C., Macchiarulo, A., Vacca, C., et al. (2014) · Nature · doi:10.1038/nature13323 · Cited by 674
Self-citationAmino Assets: How Amino Acids Support Immunity
Kelly, B., & Pearce, E. L. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.06.010 · Cited by 643
Kynurenines in the CNS: recent advances and new questions
Vécsei, L., Szalárdy, L., Fülöp, F., & Toldi, J. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3793 · Cited by 641
Holmgaard, R. B., Zamarin, D., Munn, D. H., Wolchok, J. D., & Allison, J. P. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130066 · Cited by 634
Tumor‐induced tolerance and immune suppression by myeloid derived suppressor cells
Marigo, I., Dolcetti, L., Serafini, P., Zanovello, P., & Bronte, V. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00602.x · Cited by 608
Discovery of IDO1 Inhibitors: From Bench to Bedside
Prendergast, G. C., Malachowski, W. P., DuHadaway, J. B., & Muller, A. J. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-2285 · Cited by 558
Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity
Liu, X., Shin, N., Koblish, H. K., Yang, G., Wang, Q., Wang, K., Leffet, L., Hansbury, M. J., Thomas, B., Rupar, M., et al. (2010) · Blood · doi:10.1182/blood-2009-09-246124 · Cited by 548
Immunomodulatory effects of Vitamin D in multiple sclerosis
Correale, J., Ysrraelit, M. C., & Gaitan, M. I. (2009) · Brain · doi:10.1093/brain/awp033 · Cited by 538
Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease
Romani, L., Fallarino, F., De Luca, A., Montagnoli, C., D’Angelo, C., Zelante, T., Vacca, C., Bistoni, F., Fioretti, M. C., Grohmann, U., et al. (2008) · Nature · doi:10.1038/nature06471 · Cited by 535
Self-citationIndoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer
Prendergast, G. C., Smith, C., Thomas, S., Mandik-Nayak, L., Laury-Kleintop, L., Metz, R., & Muller, A. J. (2014) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-014-1549-4 · Cited by 482
Big opportunities for small molecules in immuno-oncology
Adams, J. L., Smothers, J., Srinivasan, R., & Hoos, A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4596 · Cited by 471
Metz, R., DuHadaway, J. B., Kamasani, U., Laury-Kleintop, L., Muller, A. J., & Prendergast, G. C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1872 · Cited by 467
IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-κB activation
Puccetti, P., & Grohmann, U. (2007) · Nature Reviews Immunology · doi:10.1038/nri2163 · Cited by 453
Self-citationChen, W., Liang, X., Peterson, A. J., Munn, D. H., & Blazar, B. R. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5396 · Cited by 453
Targeting the IDO1 pathway in cancer: from bench to bedside
Liu, M., Wang, X., Wang, L., Ma, X., Gong, Z., Zhang, S., & Li, Y. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0644-y · Cited by 447
Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?
Löb, S., Königsrainer, A., Rammensee, H.-G., Opelz, G., & Terness, P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2639 · Cited by 421
Vitamin D hormone regulates serotonin synthesis. Part 1: Relevance for autism
Patrick, R. P., & Ames, B. N. (2014) · The FASEB Journal · doi:10.1096/fj.13-246546 · Cited by 414
Regulatory T-cell inhibition versus depletion: the right choice in cancer immunotherapy
Colombo, M. P., & Piconese, S. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2250 · Cited by 407
The kynurenine system and immunoregulation
Mándi, Y., & Vécsei, L. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-011-0681-y · Cited by 401
Indoleamine 2,3‐dioxygenase in T‐cell tolerance and tumoral immune escape
Katz, J. B., Muller, A. J., & Prendergast, G. C. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00610.x · Cited by 398
Lovelace, M. D., Varney, B., Sundaram, G., Lennon, M. J., Lim, C. K., Jacobs, K., Guillemin, G. J., & Brew, B. J. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.03.024 · Cited by 393
Curti, A., Pandolfi, S., Valzasina, B., Aluigi, M., Isidori, A., Ferri, E., Salvestrini, V., Bonanno, G., Rutella, S., Durelli, I., et al. (2007) · Blood · doi:10.1182/blood-2006-07-036863 · Cited by 396
Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives
Godin-Ethier, J., Hanafi, L.-A., Piccirillo, C. A., & Lapointe, R. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1331 · Cited by 392
Immune regulation through tryptophan metabolism
Seo, S.-K., & Kwon, B. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01028-7 · Cited by 390
(2010) · Advances in Cancer Research · doi:10.1016/s0065-230x(10)07003-x · Cited by 386
Immunotherapy in ovarian cancer
Odunsi, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx444 · Cited by 384
Matteoli, G., Mazzini, E., Iliev, I. D., Mileti, E., Fallarino, F., Puccetti, P., Chieppa, M., & Rescigno, M. (2010) · Gut · doi:10.1136/gut.2009.185108 · Cited by 378
Self-citationMetabolic Hallmarks of Tumor and Immune Cells in the Tumor Microenvironment
Renner, K., Singer, K., Koehl, G. E., Geissler, E. K., Peter, K., Siska, P. J., & Kreutz, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00248 · Cited by 374
Tryptophan Metabolism in Inflammaging: From Biomarker to Therapeutic Target
Sorgdrager, F. J. H., Naudé, P. J. W., Kema, I. P., Nollen, E. A., & Deyn, P. P. D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02565 · Cited by 372
Yan, Y., Zhang, G.-X., Gran, B., Fallarino, F., Yu, S., Li, H., Cullimore, M. L., Rostami, A., & Xu, H. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001628 · Cited by 358
Self-citationExpansion of Human Regulatory T-Cells From Patients With Type 1 Diabetes
Putnam, A. L., Brusko, T. M., Lee, M. R., Liu, W., Szot, G. L., Ghosh, T., Atkinson, M. A., & Bluestone, J. A. (2009) · Diabetes · doi:10.2337/db08-1168 · Cited by 357
Arginine-dependent immune responses
Martí i Líndez, A.-A., & Reith, W. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03828-4 · Cited by 354
Yang, L., Chu, Z., Liu, M., Zou, Q., Li, J., Liu, Q., Wang, Y., Wang, T., Xiang, J., & Wang, B. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01453-1 · Cited by 352
The Role of Indoleamine 2, 3-Dioxygenase in Immune Suppression and Autoimmunity
Mbongue, J., Nicholas, D., Torrez, T., Kim, N.-S., Firek, A., & Langridge, W. (2015) · Vaccines · doi:10.3390/vaccines3030703 · Cited by 351
“Tryptophan depletion was shown to induce the GCN2 pathway, to downregulate the CD3 -chain in CD8+ T-cells and to inhibit Th17 cell differentiation [14,55].”
BackgroundTwelve immunotherapy drugs that could cure cancers
‘Mac’ Cheever, M. A. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00604.x · Cited by 341
Infectious tolerance via the consumption of essential amino acids and mTOR signaling
Cobbold, S. P., Adams, E., Farquhar, C. A., Nolan, K. F., Howie, D., Lui, K. O., Fairchild, P. J., Mellor, A. L., Ron, D., & Waldmann, H. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903919106 · Cited by 336
Mondanelli, G., Bianchi, R., Pallotta, M. T., Orabona, C., Albini, E., Iacono, A., Belladonna, M. L., Vacca, C., Fallarino, F., Macchiarulo, A., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.01.005 · Cited by 333
Self-citationImmunometabolic Interplay in the Tumor Microenvironment
Kaymak, I., Williams, K. S., Cantor, J. R., & Jones, R. G. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.09.004 · Cited by 328
Creating immune privilege: active local suppression that benefits friends, but protects foes
Mellor, A. L., & Munn, D. H. (2008) · Nature Reviews Immunology · doi:10.1038/nri2233 · Cited by 327
Trial watch: IDO inhibitors in cancer therapy
Vacchelli, E., Aranda, F., Eggermont, A., Sautès-Fridman, C., Tartour, E., Kennedy, E. P., Platten, M., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/21624011.2014.957994 · Cited by 326
Immune escape as a fundamental trait of cancer: focus on IDO
Prendergast, G. C. (2008) · Oncogene · doi:10.1038/onc.2008.35 · Cited by 325
Intestinal CD103+ dendritic cells: master regulators of tolerance?
Scott, C. L., Aumeunier, A. M., & Mowat, A. M. (2011) · Trends in Immunology · doi:10.1016/j.it.2011.06.003 · Cited by 321
Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy
Grohmann, U., Volpi, C., Fallarino, F., Bozza, S., Bianchi, R., Vacca, C., Orabona, C., Belladonna, M. L., Ayroldi, E., Nocentini, G., et al. (2007) · Nature Medicine · doi:10.1038/nm1563 · Cited by 318
Self-citationMonocytes in the Tumor Microenvironment
Ugel, S., Canè, S., De Sanctis, F., & Bronte, V. (2021) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-013058 · Cited by 314
Zhang, Y., Tu, S., Ji, X., Wu, J., Meng, J., Gao, J., Shao, X., Shi, S., Wang, G., Qiu, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45636-x · Cited by 311
Control of immune response by amino acid metabolism
Grohmann, U., & Bronte, V. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00915.x · Cited by 308
Self-citationCompetition for nutrients and its role in controlling immune responses
Kedia-Mehta, N., & Finlay, D. K. (2019) · Nature Communications · doi:10.1038/s41467-019-10015-4 · Cited by 287
The therapeutic potential of targeting tryptophan catabolism in cancer
Opitz, C. A., Somarribas Patterson, L. F., Mohapatra, S. R., Dewi, D. L., Sadik, A., Platten, M., & Trump, S. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0664-6 · Cited by 300
Regulatory T cells in the treatment of disease
Sharabi, A., Tsokos, M. G., Ding, Y., Malek, T. R., Klatzmann, D., & Tsokos, G. C. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.148 · Cited by 297
Zhao, F., Xiao, C., Evans, K. S., Theivanthiran, T., DeVito, N., Holtzhausen, A., Liu, J., Liu, X., Boczkowski, D., Nair, S., et al. (2018) · Immunity · doi:10.1016/j.immuni.2017.12.004 · Cited by 289
Boasso, A., Herbeuval, J.-P., Hardy, A. W., Anderson, S. A., Dolan, M. J., Fuchs, D., & Shearer, G. M. (2007) · Blood · doi:10.1182/blood-2006-07-034785 · Cited by 288
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication
Quezada, S. A., Peggs, K. S., Simpson, T. R., & Allison, J. P. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01007.x · Cited by 276
Machine and deep learning approaches for cancer drug repurposing
Issa, N. T., Stathias, V., Schürer, S., & Dakshanamurthy, S. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.011 · Cited by 274
Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells
Wu, A. A., Drake, V., Huang, H.-S., Chiu, S., & Zheng, L. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1016700 · Cited by 271
Tuning Microenvironments: Induction of Regulatory T Cells by Dendritic Cells
Belkaid, Y., & Oldenhove, G. (2008) · Immunity · doi:10.1016/j.immuni.2008.08.005 · Cited by 268
Chung, D. J., Rossi, M., Romano, E., Ghith, J., Yuan, J., Munn, D. H., & Young, J. W. (2009) · Blood · doi:10.1182/blood-2008-11-191197 · Cited by 262
Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors
Muller, A. J., & Scherle, P. A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1929 · Cited by 262
The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology
Curti, A., Trabanelli, S., Salvestrini, V., Baccarani, M., & Lemoli, R. M. (2009) · Blood · doi:10.1182/blood-2008-07-144485 · Cited by 259
Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection
Das, A., Hoare, M., Davies, N., Lopes, A. R., Dunn, C., Kennedy, P. T. F., Alexander, G., Finney, H., Lawson, A., Plunkett, F. J., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20072076 · Cited by 256
Hendry, S. A., Farnsworth, R. H., Solomon, B., Achen, M. G., Stacker, S. A., & Fox, S. B. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00621 · Cited by 188
IDO and Kynurenine Metabolites in Peripheral and CNS Disorders
Huang, Y.-S., Ogbechi, J., Clanchy, F. I., Williams, R. O., & Stone, T. W. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00388 · Cited by 187
Jürgens, B., Hainz, U., Fuchs, D., Felzmann, T., & Heitger, A. (2009) · Blood · doi:10.1182/blood-2008-12-195073 · Cited by 176
Is There a Clinical Future for IDO1 Inhibitors After the Failure of Epacadostat in Melanoma?
Van den Eynde, B. J., van Baren, N., & Baurain, J.-F. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033635 · Cited by 175
mTOR Signaling, Tregs and Immune Modulation
Chapman, N. M., & Chi, H. (2014) · Immunotherapy · doi:10.2217/imt.14.84 · Cited by 148
Plitas, G., & Rudensky, A. Y. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033428 · Cited by 148
The Next Generation of Immunotherapy for Cancer: Small Molecules Could Make Big Waves
Kerr, W. G., & Chisholm, J. D. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1800991 · Cited by 131
Hamdi, H., Godot, V., Maillot, M.-C., Prejean, M. V., Cohen, N., Krzysiek, R., Lemoine, F. M., Zou, W., & Emilie, D. (2007) · Blood · doi:10.1182/blood-2006-10-052506 · Cited by 126
Negi, N., & Griffin, M. D. (2020) · Stem Cells · doi:10.1002/stem.3151 · Cited by 118
Harnessing FOXP3+ regulatory T cells for transplantation tolerance
Waldmann, H., Hilbrands, R., Howie, D., & Cobbold, S. (2014) · Journal of Clinical Investigation · doi:10.1172/jci67226 · Cited by 69
Sorensen, M. R., Holst, P. J., Steffensen, M. A., Christensen, J. P., & Thomsen, A. R. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.07.066 · Cited by 55
The cross-talk between opportunistic fungi and the mammalian host via microbiota’s metabolism
Romani, L., Zelante, T., Palmieri, M., Napolioni, V., Picciolini, M., Velardi, A., Aversa, F., & Puccetti, P. (2015) · Seminars in Immunopathology · doi:10.1007/s00281-014-0464-2 · Cited by 47
Self-citationAfkhami, H., Mahmoudvand, G., Fakouri, A., Shadab, A., Mahjoor, M., & Komeili Movahhed, T. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1255697 · Cited by 27
Alves de Souza, T., Fernandes-Santos, C., Araújo da Paixão de Oliveira, J., Tomé, L., Fiestas-Solórzano, V., Nunes, P., Guimaraes, G., Sánchez-Arcila, J., Paiva, I., de Souza, L., et al. (2022) · Pathogens · doi:10.3390/pathogens11040444 · Cited by 15
Metadata
- Authors
- Fallarino, F., Grohmann, U., You, S., McGrath, B. C., Cavener, D. R., Vacca, C., Orabona, C., Bianchi, R., Belladonna, M. L., Volpi, C., Santamaria, P., Fioretti, M. C., & Puccetti, P.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-06-01
- Volume
- 176
- Issue
- 11
- Pages
- 6752-6761
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2122285073
- Cited by
- 1,047
- References
- 53
- FWCI
- 16.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.